Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

This trial tests the combination of two targeted drugs — pirtobrutinib (a BTK inhibitor) and venetoclax (a BCL-2 inhibitor) — in people with Waldenström macroglobulinaemia (WM), a rare slow-growing blood cancer. Both drugs target key survival pathways in cancer cells. The study is for patients who have already received at least one prior treatment and whose disease is active and causing symptoms. **You may be eligible if...** - You are 18 or older and have been diagnosed with Waldenström macroglobulinaemia - You have had at least one previous treatment - Your disease is causing symptoms (such as fatigue, anaemia, low platelets, or neuropathy) - Your IgM protein level is measurably elevated (above twice the upper limit of normal) - Your organ function (kidneys, liver, blood counts) meets minimum criteria **You may NOT be eligible if...** - You have previously taken a non-covalent BTK inhibitor (a newer class of BTK-blocking drugs) - You had a major bleeding event or severe heart rhythm problem while on a BTK inhibitor - You have active hepatitis B or C, or HIV with active cytomegalovirus - You have cancer spread to the brain or spinal fluid - You are pregnant or breastfeeding - You are taking warfarin or strong CYP3A4-affecting medications that cannot be stopped Talk to your doctor to see if this trial is right for you.